Bad Drug » Lyrica
The pain medication Lyrica | pregabalin is an anticonvulsant drug manufactured by the pharmaceutical company Pfizer. Lyrica was the first fibromyalgia treatment approved by the FDA and is indicated for the following conditions:
For treatment of GAD, Lyrica was shown to be similar to the drugs lorazepam, Xanax | alprazolam, and Effexor | venlafaxine. Though Lyrica is best known as a pain medication, its therapeutic use for anxiety has been shown to be effective with a lower risk of the “fog” that comes with benzodiazepines such as the aforementioned drugs.
The exact mode of action for Lyrica to treat neuropathic pain disorders and anxiety as well as other mood disorders is not completely known. It is believed that Lyrica | pregablin works by calming the overly stimulated nerves that cause chronic pain disorders such as fibromyalgia. It is this same believed mechanism that reduces the symptoms of general anxiety disorder and alcohol withdrawal in individuals.
Lyrica starts off at 150 mg for all conditions that it treats. It either comes in tablet or oral solution form. The doses are divided in two or three daily incriments and daily maximum dosage ranges from:
Active ingredient: pregabalin
Inactive ingredients:
LYRICA capsules: lactose monohydrate, cornstarch, talc
Capsule shell: gelatin and titanium dioxide; Orange capsule shell: red iron oxide; White
capsule shell: sodium lauryl sulfate, colloidal silicon dioxide. Colloidal silicon dioxide is a
manufacturing aid that may or may not be present in the capsule shells.
Imprinting ink: shellac, black iron oxide, propylene glycol, potassium hydroxide.
LYRICA oral solution: methylparaben, propylparaben, monobasic sodium phosphate
anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water.
Contacting this site does not constitute an attorney - client relationship. An attorney - client relationship can be created in a written agreement.
The information included on this site is for educational purposes only. It is not intended nor implied to be a substitute for professional medical advice. The reader should always consult his or her healthcare provider. Reading the information on this website does not create a physician-patient relationship.
Copyright © © 2024 deciBel Publishing. All rights reserved.
Sitemap | Call a Lawyer
Latest FDA News
Ocaliva (obeticholic acid) by Intercept Pharmaceuticals: Drug Safety Communication - Serious Liver Injury Being Observed in Patients without CirrhosisBased on its review of postmarket clinical trial data, the U.S. Food and Drug Administration (FDA) identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did not have cirrhosis of the liver.
Find us on Google+